Tobira Therapeutics, a biotech developing an immunotherapy treatment for liver disease (NASH) and HIV, announced terms for its IPO on Monday. The San Francisco, CA-based company plans to raise $60 million by offering 4.6 million shares at a price range of $12 to $14. At the midpoint of the proposed range, Tobira would command a fully diluted market value of $150 million.
Tobira Therapeutics, which was founded in 2006, plans to list on the NASDAQ under the symbol TBRA. BMO Capital Markets, JMP Securities and Oppenheimer are the joint bookrunners on the deal It is expected to price during the week of July 28, 2014.
